RFL vs. NKGN, PLUR, VIRX, RPID, OKYO, PXDT, GYRE, DRIO, ICU, and DXR
Should you be buying Rafael stock or one of its competitors? The main competitors of Rafael include NKGen Biotech (NKGN), Pluri (PLUR), Viracta Therapeutics (VIRX), Rapid Micro Biosystems (RPID), OKYO Pharma (OKYO), Pixie Dust Technologies (PXDT), Gyre Therapeutics (GYRE), DarioHealth (DRIO), SeaStar Medical (ICU), and Daxor (DXR). These companies are all part of the "medical" sector.
Rafael (NYSE:RFL) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Rafael and NKGen Biotech both received 0 outperform votes by MarketBeat users.
Rafael has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500.
11.3% of Rafael shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 9.7% of Rafael shares are held by insiders. Comparatively, 20.0% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Rafael has a net margin of 776.36% compared to NKGen Biotech's net margin of 0.00%. NKGen Biotech's return on equity of -2.50% beat Rafael's return on equity.
NKGen Biotech has lower revenue, but higher earnings than Rafael.
In the previous week, Rafael had 10 more articles in the media than NKGen Biotech. MarketBeat recorded 12 mentions for Rafael and 2 mentions for NKGen Biotech. Rafael's average media sentiment score of 0.09 beat NKGen Biotech's score of 0.00 indicating that Rafael is being referred to more favorably in the media.
Summary
Rafael beats NKGen Biotech on 6 of the 10 factors compared between the two stocks.
Get Rafael News Delivered to You Automatically
Sign up to receive the latest news and ratings for RFL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools